Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Sep 24, 2026 - P1/2 | N=36 | Completed | Sponsor: David Bond, MD | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2026
Trial completion • Trial completion date • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Waldenstrom Macroglobulinemia
|